Zydus Lifesciences gains on getting final approval from USFDA for Theophylline Extended-Release Tablets

23 May 2024 Evaluate

Zydus Lifesciences is currently trading at Rs. 1092.70, up by 16.25 points or 1.51% from its previous closing of Rs. 1076.45 on the BSE.

The scrip opened at Rs. 1089.90 and has touched a high and low of Rs. 1104.00 and Rs. 1078.30 respectively. So far 30728 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1171.95 on 21-May-2024 and a 52 week low of Rs. 498.90 on 31-May-2023.

Last one week high and low of the scrip stood at Rs. 1171.95 and Rs. 1011.00 respectively. The current market cap of the company is Rs. 109121.05 crore.

The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.35% and 6.66% respectively.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Theophylline Extended-Release Tablets, 300 mg and 450 mg (USRLD: Theo-Dur Extended-Release Tablets). Theophylline is used to treat asthma and chronic obstructive pulmonary disease (COPD). 

The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ, India. Theophylline Extended-Release Tablets, 300 mg and 450 mg had annual sales of $12.6 million in the United States (IQVIA MAT March 2024). The group now has 396 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Zydus Lifesciences Share Price

881.95 -2.90 (-0.33%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×